A repurposed drug offers a lifeline for crush syndrome, a major cause of earthquake mortality
A new study in *Communications Medicine* demonstrates the efficacy of cilastatin sodium, a repurposed drug, in treating crush syndrome—the second-most common cause of death in earthquakes. Conducted in a translational large-animal model, the research shows that cilastatin sodium effectively ameliorates acute kidney injury and reduces the lethal elevation of blood potassium (hyperkalemia) that follows severe muscle trauma. This work addresses a critical gap in outbreak and disaster medicine, where specific pharmacological interventions for this life-threatening condition are urgently needed. The findings suggest a strong potential for rapid translation into clinical practice, offering a targeted strategy to improve survival rates in mass-casualty events and enhancing global health security and pandemic preparedness for trauma-related infectious and metabolic complications.
Study Significance: For professionals focused on infectious diseases and outbreak response, this research bridges critical care and disaster medicine, highlighting a therapeutic strategy for a condition that mimics the systemic inflammatory and septic shock seen in severe bacterial infections. It directly informs infection control and clinical management protocols for complex trauma cases, where secondary infections and sepsis are prevalent. The successful repurposing of an existing drug accelerates the pathway to deployment, providing a practical tool for improving mortality outcomes in future natural disasters and complex humanitarian emergencies.
Source →Stay curious. Stay informed — with Science Briefing.
Always double check the original article for accuracy.
